

10/579,594

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>


Uploading C:\Program Files\Stnexp\Queries\10579594b.str

L6 STRUCTURE UPLOADED

=> d

L6 HAS NO ANSWERS

L6 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l6 sss full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 191.05 U.S. DOLLARS  
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y

10/923,271

FULL SEARCH INITIATED 15:21:54 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 6969 TO ITERATE

100.0% PROCESSED 6969 ITERATIONS 74 ANSWERS  
SEARCH TIME: 00.00.01

L7 74 SEA SSS FUL L6

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

191.54

437.27

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-6.80

FILE 'CAPLUS' ENTERED AT 15:22:01 ON 26 MAR 2010  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Mar 2010 VOL 152 ISS 14  
FILE LAST UPDATED: 25 Mar 2010 (20100325/ED)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2009  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Dec 2009

Caplus now includes complete International Patent Classification (IPC) reclassification data for the first quarter of 2010.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 17

L8 107 L7

=> s 18 and py<2003

22998517 PY<2003

L9 83 L8 AND PY<2003

=> s 19 and vitamin d

10/923,271

230766 VITAMIN  
2864724 D  
33499 VITAMIN D  
(VITAMIN(W)D)

L10 69 L9 AND VITAMIN D

=> 1-10 ibib abs hitstr

1-10 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.  
For a list of commands available to you in the current file, enter  
"HELP COMMANDS" at an arrow prompt (=>).

=> y

Y IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.  
For a list of commands available to you in the current file, enter  
"HELP COMMANDS" at an arrow prompt (=>).

=> d 1-10 ibib abs hitstr

THE ESTIMATED COST FOR THIS REQUEST IS 58.10 U.S. DOLLARS  
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L10 ANSWER 1 OF 69 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2001:526056 CAPLUS

DOCUMENT NUMBER: 135:107504

TITLE: Preparation and formulations of novel vitamin  
D analogues

INVENTOR(S): Hansen, Kai Holst

PATENT ASSIGNEE(S): Leo Pharmaceutical Products Ltd. A/S, Den.

SOURCE: PCT Int. Appl., 38 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2001051464	A1	20010719	WO 2001-DK14	20010110 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,				
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,				
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,				
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,				
YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2397081	A1	20010719	CA 2001-2397081	20010110 <--
BR 2001007479	A	20020903	BR 2001-7479	20010110 <--
EP 1254111	A1	20021106	EP 2001-900108	20010110 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2002004117	A2	20030428	HU 2002-4117	20010110
HU 2002004117	A3	20040928		
JP 2003519682	T	20030624	JP 2001-551846	20010110

10/923,271

AU 775576	B2	20040805	AU 2001-23536	20010110
CN 1168726	C	20040929	CN 2001-803566	20010110
RU 2261244	C2	20050927	RU 2002-121487	20010110
US 20030004144	A1	20030102	US 2001-787664	20010320
US 6646143	B2	20031111		
MX 2002006725	A	20040910	MX 2002-6725	20020705
HK 1051197	A1	20050311	HK 2003-103464	20030516

PRIORITY APPLN. INFO.: US 2000-174924P P 20000110  
WO 2001-DK14 W 20010110

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT  
OTHER SOURCE(S): MARPAT 135:107504  
GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*


AB Vitamin D analogs of formula I [X = H, OH; R1, R2= H, (C1-C4)alkyl optionally substituted with one hydroxyl group or one or more fluorine atoms, or, together with the carbon atom to which they are attached, R1 and R2 form a (C3-C5)carbocyclic ring; R3 = (C1-C4)alkyl, (C1-C4)alkoxy, halo] and in-vivo hydrolyzable esters thereof with pharmaceutically acceptable acids, are prepared, and may be used in the prophylaxis and/or treatment of diseases characterized by abnormal cell differentiation and/or cell proliferation. Thus, II was prepared and used in a capsule, dermatol. cream, and an injectable solution

IT 115648-67-4  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation and formulations of novel vitamin D analogs for the treatment of abnormal cell differentiation or cell proliferation diseases)

RN 115648-67-4 CAPLUS

CN 1H-Indene-1-acetaldehyde, 4-[(2E)-[(3S,5R)-3,5-bis[[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro- $\alpha$ ,7a-dimethyl-, ( $\alpha$ R,1R,3aS,4E,7aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS

## RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L10 ANSWER 2 OF 69 CAPLUS COPYRIGHT 2010 ACS on STN  
 ACCESSION NUMBER: 2001:115113 CAPLUS  
 DOCUMENT NUMBER: 134:163204  
 TITLE: Synthesis of novel vitamin D analogues as pharmaceutical agents  
 INVENTOR(S): Bretting, Claus Aage Svensgaard  
 PATENT ASSIGNEE(S): Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktie, Den.  
 SOURCE: PCT Int. Appl., 55 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001010829	A1	20010215	WO 2000-DK389	20000711 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2381910	A1	20010215	CA 2000-2381910	20000711 <--
EP 1206448	A1	20020522	EP 2000-943703	20000711 <--
EP 1206448	B1	20040428		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
HU 2002002305	A2	20021028	HU 2002-2305	20000711 <--
HU 2002002305	A3	20031028		
JP 2003506435	T	20030218	JP 2001-515296	20000711
NZ 516913	A	20031128	NZ 2000-516913	20000711
AU 770771	B2	20040304	AU 2000-58072	20000711
AT 265430	T	20040515	AT 2000-943703	20000711
RU 2228928	C2	20040520	RU 2002-105520	20000711
PT 1206448	E	20040831	PT 2000-943703	20000711
CN 1167678	C	20040922	CN 2000-812345	20000711
ES 2216908	T3	20041101	ES 2000-943703	20000711
AT 420354	T	20090115	AT 2000-952321	20000731
ES 2319959	T3	20090518	ES 2000-952321	20000731
US 6573255	B1	20030603	US 2002-48363	20020201
HK 1049148	A1	20050311	HK 2003-101142	20030218
PRIORITY APPLN. INFO.:			US 1999-147200P	P 19990804
			US 1999-472654	A 19991227
			WO 2000-DK389	W 20000711

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 134:163204

GI



AB Vitamin D analogs of formula I [R = H, alkyl, Ph, aralkyl, etc.; Q = (CH<sub>2</sub>)<sub>n</sub>; n = 0-2; X = OH, halogen] are prepared. These compds. have been discovered to possess strong activity in inducing differentiation and inhibiting undesirable proliferation of certain cells as well as immunomodulating and anti-inflammatory effects (no data). Thus, II was prepared in several steps from secopregnatrienecarboxaldehyde derivative. A capsule and a dermatol. cream containing I is also described.


IT 115648-67-4

RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of novel vitamin D analogs as pharmaceutical agents)

RN 115648-67-4 CAPLUS

CN 1H-Indene-1-acetaldehyde, 4-[(2E)-[(3S,5R)-3,5-bis[[ (1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro- $\alpha$ ,7 $\alpha$ -dimethyl-, ( $\alpha$ R,1R,3aS,4E,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



OS.CITING REF COUNT:	1	THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT:	1	THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 69 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2001:113242 CAPLUS

DOCUMENT NUMBER: 134:340601

TITLE: Synthesis and biological activities of a new series of  
secosteroids: vitamin D  
phosphonate hybridsAUTHOR(S): Steinmeyer, A.; Schwarz, K.; Haberey, M.; Langer, G.;  
Wiesinger, H.CORPORATE SOURCE: Preclinical Drug Research, Schering AG, Institute of  
Medicinal Chemistry, Berlin, D-13342, Germany

SOURCE: Steroids (2001), 66(3-5), 257-266

CODEN: STEDAM; ISSN: 0039-128X

PUBLISHER: Elsevier Science Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 134:340601

AB By a structural combination of phosphonate and bisphosphonate moieties with the vitamin D skeleton a series of new vitamin D analogs was synthesized. Derivs. with 24 $\beta$ -hydroxy- or 24-keto groups exerted considerable vitamin D activities in vitro while the hypercalcemic potentials were significantly reduced as compared to 1 $\alpha$ ,25-dihydroxyvitamin D3 (calcitriol). Whereas the 24-hydroxy analogs did not influence bone formation in vivo in dosages below the hypercalcemic threshold, the 24-ketones were found to induce synthesis of new bone matrix in non-hypercalcemic doses. Vitamin D bisphosphonate hybrids, on the other hand, which did not elicit substantial vitamin D activities in vitro and tend to decrease serum calcium levels in vivo clearly induced osteoid formation in rats, indicating a mechanism of action different to calcitriol.

IT 112828-13-4


RL: RCT (Reactant); RACT (Reactant or reagent)  
(synthesis and biol. activities of vitamin D  
phosphonate hybrids)

RN 112828-13-4 CAPLUS

CN 1H-Indene-1-acetaldehyde, 4-[(2E)-2-[(3S,5R)-3,5-bis[[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro- $\alpha$ ,7a-dimethyl-,  
( $\alpha$ S,1R,3aS,4E,7aR)- (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.



IT 112924-91-1P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (synthesis and biol. activities of vitamin D phosphonate hybrids)  
 RN 112924-91-1 CAPLUS  
 CN 1H-Indene-1-acetaldehyde, 4-[(2Z)-[(3S,5R)-3,5-bis[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro- $\alpha$ ,7a-dimethyl-, ( $\alpha$ S,1R,3aS,4E,7aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)  
 REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 69 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2001:78357 CAPLUS

DOCUMENT NUMBER: 134:131708

TITLE: Preparation and bioactivity of vitamin D derivs. with cyclic substructures in the side chains

INVENTOR(S): Steinmeyer, Andreas; Schwarz, Katika; Giesen, Claudia; Haberey, Martin; Fahrnich, Marianne

PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany



10/923,271

SOURCE: PCT Int. Appl., 134 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: German  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2001007405	A2	20010201	WO 2000-EP7104	20000724 <--
WO 2001007405	A3	20020328		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
CR, CU, CZ, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,				
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,				
LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD,				
SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,				
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 19935771	A1	20010201	DE 1999-19935771	19990723 <--
CA 2376465	A1	20010201	CA 2000-2376465	20000724 <--
BR 2000013175	A	20020402	BR 2000-13175	20000724 <--
EP 1210327	A2	20020605	EP 2000-962278	20000724 <--
EP 1210327	B1	20060118		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, MK, CY, AL				
HU 2002002015	A2	20021028	HU 2002-2015	20000724 <--
HU 2002002015	A3	20040428		
JP 2003505447	T	20030212	JP 2001-512492	20000724
EE 200200036	A	20030415	EE 2002-36	20000724
EE 5027	B1	20080616		
US 6603031	B1	20030805	US 2000-624608	20000724
EP 1362848	A1	20031119	EP 2003-90212	20000724
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, CY				
NZ 515891	A	20040326	NZ 2000-515891	20000724
AU 773673	B2	20040603	AU 2000-74072	20000724
AT 316073	T	20060215	AT 2000-962278	20000724
ES 2254222	T3	20060616	ES 2000-962278	20000724
IL 147634	A	20061031	IL 2000-147634	20000724
EE 200800025	A	20080616	EE 2008-25	20000724
IN 2001MN01587	A	20060106	IN 2001-MN1587	20011213
MX 2001013330	A	20020709	MX 2001-13330	20011219 <--
BG 106334	A	20020628	BG 2002-106334	20020121 <--
NO 2002000330	A	20020322	NO 2002-330	20020122 <--
ZA 2002001482	A	20030521	ZA 2002-1482	20020221
US 20030149006	A1	20030807	US 2002-303916	20021126
US 7115758	B2	20061003		
IN 2005MN01178	A	20070706	IN 2005-MN1178	20051025
IN 2005MN01185	A	20070817	IN 2005-MN1185	20051025
PRIORITY APPLN. INFO.:			DE 1999-19935771	A 19990723
			EE 2002-36	A 20000724
			EP 2000-962278	A3 20000724
			US 2000-624608	A3 20000724
			WO 2000-EP7104	W 20000724
			IN 2001-MN1587	A3 20011213

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT  
OTHER SOURCE(S):                MARPAT 134:131708  
GI

AB The invention describes the synthesis of vitamin D  
derivs. [I; Y1, Y2 = OH, alkanoyloxy, aroyloxy; R1, R2 = H; R1R2 = CH2;  
R3, R4 = H, Cl, F, alkyl, etc.; Q = alkylene chain; X1, X2 = H, OH, Cl, F,  
Br, etc.; Z = (un)substituted, (un)saturated or aromatic 5-, 6-membered carbo-,  
heterocyclic ring], the intermediates used in the process, and the production  
of medicaments. Thus, vitamin D analog II was prepared  
via Wittig reaction of ketone III (also prepared) with IV, followed by  
deprotection. II had competition factor of 5 vs. calcitriol towards  
receptor binding and dose relation for differentiation induction in HL 60  
cell.

IT 112924-91-1  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation and bioactivity of vitamin D derivs. with  
cyclic substructures in the side chains)

RN 112924-91-1 CAPLUS

CN 1H-Indene-1-acetaldehyde, 4-[(2Z)-[(3S,5R)-3,5-bis[[1,1-  
dimethylethyl]dimethylsilyl]oxy]-2-  
methylenecyclohexylidene]ethylidene]octahydro- $\alpha$ ,7a-dimethyl-,  
( $\alpha$ S,1R,3aS,4E,7aR)- (9CI) (CA INDEX NAME)

```
L10  ANSWER 5 OF 69  CAPLUS  COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER:      2000:772606  CAPLUS
DOCUMENT NUMBER:      133:322045
TITLE:                 Synthesis, activity and formulations of
                        vitamin D analogs
```

10/923,271


INVENTOR(S): Hansen, Kai  
PATENT ASSIGNEE(S): Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske  
Fabrik Produktionsaktie, Den.  
SOURCE: PCT Int. Appl., 26 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000064869	A1	20001102	WO 2000-DK177	20000412 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2371165	A1	20001102	CA 2000-2371165	20000412 <--
EP 1178960	A1	20020213	EP 2000-918712	20000412 <--
EP 1178960	B1	20031105		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
HU 2002000812	A2	20020828	HU 2002-812	20000412 <--
HU 2002000812	A3	20030728		
JP 2002543062	T	20021217	JP 2000-613822	20000412 <--
NZ 515138	A	20031031	NZ 2000-515138	20000412
AT 253555	T	20031115	AT 2000-918712	20000412
AU 768037	B2	20031127	AU 2000-39567	20000412
RU 2223953	C2	20040220	RU 2001-131557	20000412
PT 1178960	E	20040331	PT 2000-918712	20000412
CN 1152011	C	20040602	CN 2000-807644	20000412
ES 2208300	T3	20040616	ES 2000-918712	20000412
US 6537980	B1	20030325	US 2001-959306	20011023
HK 1045497	A1	20041203	HK 2002-107026	20020926
PRIORITY APPLN. INFO.:			GB 1999-9442	A 19990423
			US 1999-130638P	P 19990423
			WO 2000-DK177	W 20000412

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 133:322045

GI



AB Synthesis, activity and formulations of vitamin D analogs (I) (R1 and R2, which may be the same or different, = alkyl; R3 = H, halogen, alkyl, alkoxy) and in-vivo hydrolyzable esters thereof with pharmaceutically acceptable acids is disclosed. Thus, I (R1, R2 = Me, R3 = H) (II) is prepared by reaction of 2-(2-(3-bromomethylphenyl)-2-propyloxy)tetrahydro-4H-pyran with 20(R)-silyl-protected-tosyloxysecopregnatriene followed by desilylation with HF in acetonitrile. II exhibits considerably less skin irritation than compds. of prior art. The present compds. are of value in the human and veterinary practice.


IT 134523-96-9

RL: RCT (Reactant); RACT (Reactant or reagent)  
(synthesis, activity and formulations of vitamin D analogs)

RN 134523-96-9 CAPLUS

CN 1H-Indene-1-acetaldehyde, 4-[(2Z)-[(3S,5R)-3,5-bis[[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro- $\alpha$ ,7a-dimethyl-, ( $\alpha$ R,1R,3aS,4E,7aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD


10/923,271

(2 CITINGS)  
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 6 OF 69 CAPLUS COPYRIGHT 2010 ACS on STN  
ACCESSION NUMBER: 2000:464966 CAPLUS  
DOCUMENT NUMBER: 133:89679  
TITLE: Preparation of vitamin D  
intermediates  
INVENTOR(S): Koga, Masahiro; Minoshima, Toru  
PATENT ASSIGNEE(S): Teijin Ltd., Japan  
SOURCE: Jpn. Kokai Tokkyo Koho, 16 pp.  
CODEN: JKXXAF  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000191637	A	20000711	JP 1998-367558	19981224 <--
WO 2001074764	A1	20011011	WO 2000-JP2033	20000330 <--
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 2000034564	A	20011015	AU 2000-34564	20000330 <--
EP 1270556	A1	20030102	EP 2000-912984	20000330
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
US 6753435	B1	20040622	US 2002-239778	20020925
PRIORITY APPLN. INFO.:			JP 1998-367558	A 19981224
			WO 2000-JP2033	A 20000330

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT  
OTHER SOURCE(S): CASREACT 133:89679; MARPAT 133:89679  
GI



AB Synthetic intermediates I [R<sub>1</sub>, R<sub>2</sub> = H, silyl group, acetal, ester] of 1 $\alpha$ -hydroxyvitamin D derivs. are prepared. Reacting the compound of formula II and the compound of formula III using a palladium catalyst, then deoxidization with Lindlar catalyst and hydrogen gas, and then heating and oxidation produces compound I. Thus, I (R<sub>1</sub> = R<sub>2</sub> = tert-butyldimethylsilyl) is prepared.

IT 112924-91-1P


RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(preparation of vitamin D intermediates)

RN 112924-91-1 CAPLUS

CN 1H-Indene-1-acetaldehyde, 4-[(2Z)-[(3S,5R)-3,5-bis[[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro- $\alpha$ ,7a-dimethyl-, ( $\alpha$ S,1R,3aS,4E,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



L10 ANSWER 7 OF 69 CAPLUS COPYRIGHT 2010 ACS on STN  
ACCESSION NUMBER: 2000:71439 CAPLUS  
DOCUMENT NUMBER: 132:237242

TITLE: Synthesis and biological activity of 22-iodo- and (E)-20(22)-dehydro analogues of 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>  
 AUTHOR(S): Sicinski, Rafal R.; DeLuca, Hector F.  
 CORPORATE SOURCE: Department of Biochemistry, College of Agricultural and Life Sciences, University of Wisconsin-Madison, Madison, WI, 53706, USA  
 SOURCE: Bioorganic & Medicinal Chemistry (1999), 7(12), 2877-2889  
 CODEN: BMECEP; ISSN: 0968-0896  
 PUBLISHER: Elsevier Science Ltd.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English


AB Construction of 25-hydroxy-steroidal side chain substituted with iodine at C-22 was elaborated on a model PTAD-protected steroidal 5,7-diene and applied to a synthesis of (22R)- and (22S)-22-iodo-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>. Configuration at C-22 in the iodinated vitamins, obtained by nucleophilic substitution of the corresponding 22S-tosylates with sodium iodide, was determined by comparison of their iodine-displacement processes and cyclizations leading to isomeric five-membered (22,25)-epoxy-1 $\alpha$ -hydroxyvitamin D<sub>3</sub> compds. Also, 20(22)-dehydrosteroids have been obtained and their structures established by 1H NMR spectroscopy. When compared to the natural hormone, (E)-20(22)-dehydro-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> was found 4 times less potent in binding to the porcine intestinal vitamin D receptor (VDR) and 2 times less effective in differentiation of HL-60 cells. 22-Iodinated vitamin D analogs showed somewhat lower in vitro activity, whereas (22,25)-epoxy analogs were inactive. Interestingly, it was established that (22S)-22-iodo-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> was 3 times more potent than its (22R)-isomer in binding to VDR and four times more effective in HL-60 cell differentiation assay. The restricted mobility of the side chain of both 22-iodinated vitamin D compds. was analyzed by a systematic conformational search indicating different spatial regions occupied by their 25-oxygen atoms. Preliminary data on the in vivo calcemic activity of the synthesized vitamin D analogs indicate that (E)-20(22)-dehydro-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> and 22-iodo-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> isomers were ca. ten times less potent than the natural hormone 1 $\alpha$ ,25-(OH)<sub>2</sub>D<sub>3</sub> both in intestinal calcium transport and bone calcium mobilization.

IT 112924-91-1  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (synthesis and biol. activity of 22-iodo- and (E)-20(22)-dehydro analogs of 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>)

RN 112924-91-1 CAPLUS

CN 1H-Indene-1-acetaldehyde, 4-[(2Z)-[(3S,5R)-3,5-bis[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro- $\alpha$ ,7a-dimethyl-, ( $\alpha$ S,1R,3aS,4E,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.



OS.CITING REF COUNT: 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD  
(9 CITINGS)  
REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 8 OF 69 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1999:764017 CAPLUS

DOCUMENT NUMBER: 132:3501

TITLE: Preparation of hydroxy-25-ene-vitamin  
D compounds

INVENTOR(S): Wynberg, Hans; Vries, Ton; Pouwer, Kees

PATENT ASSIGNEE(S): Bone Care International, Inc., USA

SOURCE: PCT Int. Appl., 42 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9961417	A2	19991202	WO 1999-US11950	19990528 <--
WO 9961417	A3	20000113		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2333256	A1	19991202	CA 1999-2333256	19990528 <--
AU 9943209	A	19991213	AU 1999-43209	19990528 <--
AU 755701	B2	20021219		
BR 9910692	A	20010109	BR 1999-10692	19990528 <--
EP 1091936	A2	20010418	EP 1999-953335	19990528 <--
EP 1091936	B1	20030730		
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2002516306	T	20020604	JP 2000-550823	19990528 <--
AT 246172	T	20030815	AT 1999-953335	19990528
ES 2204165	T3	20040416	ES 1999-953335	19990528
CN 1148347	C	20040505	CN 1999-806788	19990528




10/923,271

IL 139354	A	20050831	IL 1999-139354	19990528
MX 2000011210	A	20010419	MX 2000-11210	20001115 <--
US 6441207	B1	20020827	US 2000-716316	20001120 <--
US 20030009042	A1	20030109	US 2002-228002	20020826

PRIORITY APPLN. INFO.:  
US 1998-87222P P 19980529  
WO 1999-US11950 W 19990528  
US 2000-716316 A3 20001120

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT  
OTHER SOURCE(S): CASREACT 132:3501  
GI




AB Novel vitamin D compds., e.g. of formula I [Y = Me, CH<sub>2</sub>, H; R<sub>1</sub> = H, OH; R<sub>2</sub> = H, alkyl, fluoroalkyl; R<sub>3</sub>, R<sub>6</sub>, R<sub>7</sub> = H, alkyl, alkenyl, fluoroalkyl, fluoroalkenyl; R<sub>4</sub>, R<sub>5</sub> = alkyl, alkenyl, fluoroalkyl, fluoroalkenyl], in which the C-25 or equivalent position has a double bond, are prepared. In addition, the side chain is optionally extended by one or two methylene or methyne groups. The compds. prepared by the method of the present invention are of value as prodrugs for active 1 $\alpha$ ,24-dihydroxylated vitamin D compds (no data). Thus, 1 $\alpha$ -hydroxy-25-ene-vitamin D<sub>2</sub> was prepared from Et dimethylacrylate and vitamin D<sub>2</sub> in many steps.

IT 112828-13-4P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of hydroxy-25-ene-vitamin D compds. as prodrugs)

RN 112828-13-4 CAPLUS

CN 1H-Indene-1-acetaldehyde, 4-[(2E)-2-[(3S,5R)-3,5-bis[[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro- $\alpha$ ,7a-dimethyl-, ( $\alpha$ S,1R,3aS,4E,7aR)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD  
(2 CITINGS)  
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 9 OF 69 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1999:763999 CAPLUS

DOCUMENT NUMBER: 132:12446

TITLE: synthesis and biological activity of 24-hydroxyvitamin  
D and analogs

INVENTOR(S): Bishop, Charles W.; Knutson, Joyce C.; Strugnell,  
Stephen

PATENT ASSIGNEE(S): Bone Care International, USA

SOURCE: PCT Int. Appl., 57 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 20

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9961398	A2	19991202	WO 1999-US12084	19990528 <--
WO 9961398	A3	20001123		
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6242434	B1	20010605	US 1998-86969	19980529 <--
CA 2332146	A1	19991202	CA 1999-2332146	19990528 <--
EP 1080055	A2	20010307	EP 1999-953332	19990528 <--
EP 1080055	B1	20030924		
R:	AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE, PT, IE, FI			
JP 2002516299	T	20020604	JP 2000-550810	19990528 <--
AU 757740	B2	20030306	AU 1999-43243	19990528
AT 250566	T	20031015	AT 1999-953332	19990528
NZ 507855	A	20031128	NZ 1999-507855	19990528
IL 139355	A	20050831	IL 1999-139355	19990528

10/923,271

MX 2000011214 A 20010419 MX 2000-11214 20001115 <--  
PRIORITY APPLN. INFO.: US 1998-86969 A 19980529  
US 1997-907659 A2 19970808  
WO 1999-US12084 W 19990528

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 132:12446

AB Synthesis of 24-hydroxyvitamin D compds. and their use in the treatment and prophylaxis of hyperparathyroidism and hyperproliferative diseases, and in the modulation of the immune and inflammatory responses as well as the treatment of bone depletive disorders is disclosed.

IT 251445-18-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(synthesis and biol. activity of 24-hydroxyvitamin D and analogs)

RN 251445-18-8 CAPLUS

CN 1H-Indene-1-acetaldehyde, 4-[[[(4S)-4-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1,3,4,5,6,7-hexahydro-2,2-dioxidobenzo[c]thien-1-yl]methylene]octahydro- $\alpha$ ,7a-dimethyl-, ( $\alpha$ S,1R,3aS,4E,7aR)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as described by E or Z.



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)  
REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 10 OF 69 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1999:404974 CAPLUS

DOCUMENT NUMBER: 131:59020

TITLE: Preparation of vitamin D derivatives with phosphorous atoms in the side chains  
INVENTOR(S): Steinmeyer, Andreas; Neef, Gunter; Kirsch, Gerald; Schwarz, Katica; Wiesinger, Herbert; Haberey, Martin; Fahnrich, Marianne; Langer, Gernot

PATENT ASSIGNEE(S): Schering A.-G., Germany

SOURCE: PCT Int. Appl., 105 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9931112	A1	19990624	WO 1998-EP8137	19981216 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 927721	A1	19990707	EP 1997-250374	19971217 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
DE 19758119	C1	19990729	DE 1997-19758119	19971217 <--
AU 9924134	A	19990705	AU 1999-24134	19981216 <--
EP 1042335	A1	20001011	EP 1998-966616	19981216 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002508383	T	20020319	JP 2000-539035	19981216 <--
US 6531459	B1	20030311	US 2000-581907	20000804
PRIORITY APPLN. INFO.:			DE 1997-19758119	A 19971217
			EP 1997-250374	A 19971217
			WO 1998-EP8137	W 19981216
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S): MARPAT 131:59020				
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The invention relates to novel vitamin D derivs. I [Y1 = H, OH, F, Cl, Br, O2CR5; Y2 = H, COR6; Y2O =  $\alpha$ - or  $\beta$ - bond; R1, R2 = H; R1R2 = CH2; R3, R4 = H, Cl, F, C1-4-alkyl; R3R4 = CH2; R3R4-C(20) = saturated or unsatd. C3-7-cycloalkyl; R5, R6 = C1-12-alkyl, aryl; VW = bond; V = W = OH; V = OH, W = H; X1, X2 = H, OH, OR7, O2CR7, PO(OR8)2, PO(NR82)2, PO(R8)2, OPO(OR8)2, OPO(NR82)2, OPO(R8)2, CH2PO(OR8)2, CH2PO(NR82)2, CH2PO(R8)2; R7 = C1-12-alkyl, aryl; R8 = H, C1-12-alkyl, aryl;; X1X2 = O; n = 0, 1; E1 = PO(OR9)2, PO(NR92)2, PO(R9)2, CO2R9; R9 = H, C1-12-alkyl, aryl; E2 = PO(OR9)2, PO(NR92)2, PO(R9)2, CO2R9, F, Cl, Br, H, C1-12-alkyl, aryl; Q = H, C1-12-alkyl, aryl, OH, O2CR10, F, Cl, Br, NH2, NHR10, N(R10)2; R10 = C1-12-alkyl, aryl; X1E2 = bond, X2 = H, OZ; Z = C1-12-alkyl, aryl, C1-12-acyl, aroyl, E2; X1X2E2Q = triple bond], a method for their production, intermediate products of the method as well as their use in producing medicaments. Thus, vitamin D analog II was prepared from aldehyde III (TBDMS = SiMe2CMe3), via photochem. E/Z-isomerization, Horner-Emmons reaction with (MeO)2P(O)CH2CO2Me, condensation of unsatd. ester IV with MeP(O)(OMe)2 and desilylation with Dowex ion-exchange resin. II has an affinity for calcitriol receptors (competition factor = 10) and shows differentiation induction for HL-60 cells [DR50 = 22] and hypercalcemia induction [DR50 = >>100].


IT 112828-13-4, (1S,3R,5E,7E)-1,3-Bis[(tert-butylidimethylsilyl)oxy]9,10-secopregna-5,7,10(19)-triene-20-carboxaldehyde

RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation and bioactivity of vitamin D derivs. with  
 phosphorous atoms in the side chains)

RN 112828-13-4 CAPLUS

CN 1H-Indene-1-acetaldehyde, 4-[(2E)-2-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro- $\alpha$ ,7a-dimethyl-, ( $\alpha$ S,1R,3aS,4E,7aR)- (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.




IT 112924-91-1P, (1S,3R,5Z,7E)-1,3-Bis[(tert-butyl)dimethylsilyl]oxy]9,10-secopregna-5,7,10(19)-triene-20-carboxaldehyde  
 227748-28-9P 227748-29-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation and bioactivity of vitamin D derivs. with  
 phosphorous atoms in the side chains)

RN 112924-91-1 CAPLUS

CN 1H-Indene-1-acetaldehyde, 4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro- $\alpha$ ,7a-dimethyl-, ( $\alpha$ S,1R,3aS,4E,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.




10/923,271

RN 227748-28-9 CAPLUS

CN 1H-Indene-1-acetaldehyde, 4-[(2E)-2-[(3S,5S)-3,5-bis[[ (1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro- $\alpha$ ,7a-dimethyl-, ( $\alpha$ S,1R,3aS,4E,7aR)- (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 227748-29-0 CAPLUS

CN 1H-Indene-1-acetaldehyde, 4-[(2Z)-2-[(3S,5S)-3,5-bis[[ (1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro- $\alpha$ ,7a-dimethyl-, ( $\alpha$ S,1R,3aS,4E,7aR)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



OS.CITING REF COUNT:	5	THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
REFERENCE COUNT:	5	THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/923,271

=> d 59-69 ibib abs hitstr

THE ESTIMATED COST FOR THIS REQUEST IS 63.91 U.S. DOLLARS  
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L10 ANSWER 59 OF 69 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1990:119244 CAPLUS

DOCUMENT NUMBER: 112:119244

ORIGINAL REFERENCE NO.: 112:20215a,20218a

TITLE: Vitamin D homologs for treatment  
of neoplastic diseases

INVENTOR(S): Deluca, Hector F.; Schnoes, Heinrich K.; Perlman, Kato  
L.

PATENT ASSIGNEE(S): Wisconsin Alumni Research Foundation, USA

SOURCE: Brit. UK Pat. Appl., 35 pp.

CODEN: BAXXDU

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2217716	A	19891101	GB 1989-9573	19890426 <--
WO 8910352	A1	19891102	WO 1989-US1632	19890418 <--
W: AU, CH, DE, DK, GB, HU, JP, KR, NL, SU				
RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
AU 8935533	A	19891124	AU 1989-35533	19890418 <--
AU 629831	B2	19921015		
NL 8920392	A	19900402	NL 1989-20392	19890418 <--
EP 374219	A1	19900627	EP 1989-905565	19890418 <--
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
HU 52476	A2	19900728	HU 1989-4747	19890418 <--
HU 206316	B	19921028		
JP 02504149	T	19901129	JP 1989-505246	19890418 <--
JP 06099454	B	19941207		
RU 2057117	C1	19960327	RU 1989-4742994	19890418 <--
IL 90065	A	19960514	IL 1989-90065	19890424 <--
FR 2630739	A1	19891103	FR 1989-5752	19890428 <--
IN 169818	A1	19911228	IN 1989-DE384	19890501 <--
DK 8906659	A	19900228	DK 1989-6659	19891222 <--
US 5250523	A	19931005	US 1990-481993	19900214 <--
US 5354744	A	19941011	US 1992-999537	19921231 <--
PRIORITY APPLN. INFO.:			US 1988-187675	A 19880429
			WO 1989-US1632	A 19890418
			US 1989-428139	B2 19891030
			US 1990-488465	B1 19900226

OTHER SOURCE(S): MARPAT 112:119244  
GI



AB Title steroids I (X, Y, Z = H or hydroxy-protecting group; n = 3, 4) were prepared as cell differentiation-inducing agents for treatment of neoplastic diseases. Thus, I (X = Y = Z = H; n = 3 and 4) were prepared from 3 $\beta$ -acetoxy-22,23-bisnor-5-cholenic acid in 15 steps via the aldehyde-sulfone reaction products II (X = Y = SiMe<sub>2</sub>CMe<sub>3</sub>). In tests for differentiation of HL-60 human leukemia cells in culture, I (X = Y = Z = H; n = 3) was approx. 5 times as potent as 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>, but was many times less potent in its calcemic activity.

IT 112924-91-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and reaction of, in preparation of antineoplastic vitamin D homologs)


RN 112924-91-1 CAPLUS

CN 1H-Indene-1-acetaldehyde, 4-[(2Z)-[(3S,5R)-3,5-bis[[ (1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro- $\alpha$ ,7a-dimethyl-, ( $\alpha$ S,1R,3aS,4E,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




10/923,271



IT 111024-92-1P 116391-23-2P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, in preparation of antineoplastic vitamin D  
homologs)  
RN 111024-92-1 CAPLUS  
CN 1H-Indene-1-acetaldehyde, 4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-  
methylenecyclohexylidene]ethylidene]octahydro- $\alpha$ ,7a-dimethyl-,  
( $\alpha$ S,1R,3aS,4E,7aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 116391-23-2 CAPLUS  
CN 1H-Indene-1-acetaldehyde, octahydro-4-[(5-hydroxy-2-  
methylenecyclohexylidene)ethylidene]- $\alpha$ ,7a-dimethyl-,  
[1R-[1 $\alpha$ (S\*),3a $\beta$ ,4E(1Z,5S\*),7a $\alpha$ ]]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

10/923,271



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD  
(5 CITINGS)

L10 ANSWER 60 OF 69 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1990:70146 CAPLUS

DOCUMENT NUMBER: 112:70146

ORIGINAL REFERENCE NO.: 112:11791a,11794a

TITLE: 24-Homologated 1,25-dihydroxyvitamin D<sub>3</sub> compounds:  
separation of calcium and cell differentiation  
activities

AUTHOR(S): Perlman, Kato; Kutner, Andrzej; Prahl, Jean; Smith,  
Connie; Inaba, Masaaki; Schnoes, Heinrich K.; DeLuca,  
H. F.


CORPORATE SOURCE: Coll. Agric. Life Sci., Univ. Wisconsin, Madison, WI,  
53706, USA

SOURCE: Biochemistry (1990), 29(1), 190-6  
CODEN: BICHAW; ISSN: 0006-2960

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



I

AB A series of 24-homologated 1,25-dihydroxyvitamin D<sub>3</sub> (I) compds. was synthesized and studied with regard to their activity in inducing differentiation of human promyelocyte HL-60 cells to monocytes and in Ca-mobilizing activity in vitamin D-deficient rats. Homologation of I or its  $\Delta^{22}$  analog by 1 or 2 carbons increases by 10-fold and 3-carbon homologation reduces by 50% the activity causing differentiation of HL-60. On the other hand, homologation causes a substantial decrease in in vivo calcium mobilization activity. The addition

10/923,271

of each carbon at the 24-position decreases binding to the HL-60 receptor or rat intestinal receptor by 5-10-fold so that binding affinity of the trihomo compound for the receptors is 130-times less than that of I. Thus, binding affinity for the receptor cannot account for the preferential activity of the 24-homologated compds. in inducing cell differentiation.

IT 112924-91-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation and reaction of, with triethylsiloxyalkyl phenylsulfones)

RN 112924-91-1 CAPLUS

CN 1H-Indene-1-acetaldehyde, 4-[(2Z)-[(3S,5R)-3,5-bis[[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro- $\alpha$ ,7 $\alpha$ -dimethyl-, ( $\alpha$ S,1R,3aS,4E,7aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



OS.CITING REF COUNT: 33 THERE ARE 33 CAPLUS RECORDS THAT CITE THIS RECORD (33 CITINGS)

L10 ANSWER 61 OF 69 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1990:36264 CAPLUS

DOCUMENT NUMBER: 112:36264

ORIGINAL REFERENCE NO.: 112:6289a,6292a

TITLE: Preparation of secosteroid intermediates for vitamin D-related compounds

INVENTOR(S): DeLuca, Hector F.; Schnoes, Heinrich K.; Kutner, Andrzej; Perlman, Kato L.; Sicinski, Rafal R.; Phelps, Mary E.

PATENT ASSIGNEE(S): Wisconsin Alumni Research Foundation, USA

SOURCE: U.S., 11 pp.  
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4847012	A	19890711	US 1988-188334	19880429 <--
PRIORITY APPLN. INFO.:			US 1988-188334	19880429

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT  
OTHER SOURCE(S): CASREACT 112:36264; MARPAT 112:36264  
GI

AB Secosteroids I (X, Y = H, protecting group; W = CHO, alkoxycarbonyl, aryloxycarbonyl), useful as intermediates for vitamin D derivs. which are useful for control of Ca and phosphate metabolism, are prepared Irradiation of pregnadienecarboxylate II (preparation given) in benzene-Et<sub>2</sub>O with a Hanovia 608A36 medium-pressure UV lamp for 40 min gave the hydroxy secosteroid III, which was converted to the O-tosyl derivative, which was then cyclized in CH<sub>2</sub>Cl<sub>2</sub> with methanolic KHCO<sub>3</sub> at 55° to give the cyclosecosteroid IV (Z = H). This was treated with Me<sub>3</sub>COOH and SeO<sub>2</sub> in toluene-CH<sub>2</sub>Cl<sub>2</sub> to give IV (Z = OH), which was heated with HOAc at 55° to give I (X = Ac, Y = H, W = CO<sub>2</sub>Me) and its 5(E)-isomer. Conversions of the above I into I [X, Y = H, protecting group; W = (R)-CH:CHCHMeCMe<sub>2</sub>OH] and their derivs. are also described.


CN 1H-Indene-1-acetaldehyde, octahydro-4-[(5-hydroxy-2-methylenecyclohexylidene)ethylidene]- $\alpha$ ,7a-dimethyl-, [1R-[1 $\alpha$ (S\*),3 $\alpha$ ,4E(1Z,5S\*),7 $\alpha\alpha$ ]]- (9CI) (CA INDEX NAME)

```


IT      111024-92-1P      112924-91-1P
      RL: SPN (Synthetic preparation); PREP (Preparation)
           (preparation of, from acetoxybisanthracenic acid)
RN      111024-92-1      CAPLUS
CN      1H-Indene-1-acetaldehyde, 4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-
      methylenecyclohexylidene]ethylidene]octahydro- $\alpha$ ,7a-dimethyl-,
      ( $\alpha$ S,1R,3aS,4E,7aR)- (9CI) (CA INDEX NAME)

```

Absolute stereochemistry.  
Double bond geometry as shown.




Absolute stereochemistry.  
Double bond geometry as shown.



L10 ANSWER 62 OF 69 CAPLUS COPYRIGHT 2010 ACS on STN  
ACCESSION NUMBER: 1988:549862 CAPLUS  
DOCUMENT NUMBER: 109:149862  
ORIGINAL REFERENCE NO.: 109:24943a,24946a  
TITLE: Vitamin D C-22 aldehydes. New key  
intermediates for the synthesis of side chain modified  
vitamin D analogs  
AUTHOR(S): Kutner, Andrzej; Perlman, Kato L.; Sicinski, Rafal R.;  
Phelps, Mary E.; Schnoes, Heinrich K.; DeLuca, Hector  
F.  
CORPORATE SOURCE: Coll. Agric. Life Sci., Univ. Wisconsin, Madison, WI,


10/923,271

SOURCE: 53706, USA  
Tetrahedron Letters (1987), 28(49), 6129-32  
CODEN: TELEAY; ISSN: 0040-4039  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 109:149862  
GI



AB Vitamin D C-22 aldehyde (I) and  
1 $\alpha$ -hydroxyvitamin D C-22 aldehyde were prepared from  
22,23-bisnorcholeonic acid. The usefulness of the compds. as common  
intermediates for the synthesis of side chain modified analogs of vitamins  
D2 and D3 was demonstrated.  
IT 111024-92-1P 116391-23-2P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)  
RN 111024-92-1 CAPLUS  
CN 1H-Indene-1-acetaldehyde, 4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-  
methylenecyclohexylidene]ethylidene]octahydro- $\alpha$ ,7a-dimethyl-,  
( $\alpha$ S,1R,3aS,4E,7aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



10/923,271


RN 116391-23-2 CAPLUS  
CN 1H-Indene-1-acetaldehyde, octahydro-4-[(5-hydroxy-2-methylenecyclohexylidene)ethylidene]- $\alpha$ ,7a-dimethyl-, [1R-[1 $\alpha$ (S\*),3 $\alpha$ ,4E(1Z,5S\*),7 $\alpha$ ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



IT 112924-91-1P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, in synthesis of vitamin D analogs)  
RN 112924-91-1 CAPLUS  
CN 1H-Indene-1-acetaldehyde, 4-[(2Z)-[(3S,5R)-3,5-bis[[1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro- $\alpha$ ,7a-dimethyl-, ( $\alpha$ S,1R,3aS,4E,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD  
(6 CITINGS)

L10 ANSWER 63 OF 69 CAPLUS COPYRIGHT 2010 ACS on STN  
ACCESSION NUMBER: 1988:473746 CAPLUS  
DOCUMENT NUMBER: 109:73746  
ORIGINAL REFERENCE NO.: 109:12365a,12368a  
TITLE: Synthesis of MC 903, a biologically active

10/923,271

vitamin D metabolite analog  
AUTHOR(S): Calverley, Martin J.  
CORPORATE SOURCE: Leo Pharm. Prod., Ballerup, DK-2750, Den.  
SOURCE: Tetrahedron (1987), 43(20), 4609-19  
CODEN: TETRAB; ISSN: 0040-4020  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 109:73746  
GI



I

AB MC 903 (I), a 1,24-dihydroxyvitamin D analog, was synthesized in 12 steps from vitamin D2.


IT 112828-13-4P 115648-65-2P 115648-66-3P  
115648-67-4P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, during synthesis of analogs of vitamin D  
metabolites)

RN 112828-13-4 CAPLUS

CN 1H-Indene-1-acetaldehyde, 4-[(2E)-2-[(3S,5R)-3,5-bis[[ (1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro- $\alpha$ ,7 $\alpha$ -dimethyl-, ( $\alpha$ S,1R,3 $\alpha$ S,4E,7 $\alpha$ R)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.






10/923,271

RN 115648-65-2 CAPLUS

CN 1H-Indene-1-acetaldehyde, 4-[[ (1S,4S,6R)-4,6-bis[[ (1,1-dimethylethyl)dimethylsilyl]oxy]-1,3,4,5,6,7-hexahydro-2,2-dioxidobenzo[c]thien-1-yl]methylene]octahydro- $\alpha$ ,7a-dimethyl-, ( $\alpha$ R,1R,3aS,4E,7aR)- (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 115648-66-3 CAPLUS

CN 1H-Indene-1-acetaldehyde, 4-[[ (1R,4S,6R)-4,6-bis[[ (1,1-dimethylethyl)dimethylsilyl]oxy]-1,3,4,5,6,7-hexahydro-2,2-dioxidobenzo[c]thien-1-yl]methylene]octahydro- $\alpha$ ,7a-dimethyl-, ( $\alpha$ R,1R,3aS,4E,7aR)- (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 115648-67-4 CAPLUS

CN 1H-Indene-1-acetaldehyde, 4-[(2E)-[(3S,5R)-3,5-bis[[ (1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro- $\alpha$ ,7a-dimethyl-, ( $\alpha$ R,1R,3aS,4E,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



OS.CITING REF COUNT: 60 THERE ARE 60 CAPLUS RECORDS THAT CITE THIS RECORD (60 CITINGS)

L10 ANSWER 64 OF 69 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1988:455060 CAPLUS

DOCUMENT NUMBER: 109:55060

ORIGINAL REFERENCE NO.: 109:9299a,9302a

TITLE: Novel convergent synthesis of side-chain-modified analogs of 1 $\alpha$ ,25-dihydroxycholecalciferol and 1 $\alpha$ ,25-dihydroxyergocalciferol

AUTHOR(S): Kutner, Andrzej; Perlman, Kato L.; Lago, Amparo; Schnoes, Heinrich K.; DeLuca, H. F.; Sicinski, Rafal R.

CORPORATE SOURCE: Coll. Agric. Life Sci., Univ. Wisconsin, Madison, WI, 53706, USA

SOURCE: Journal of Organic Chemistry (1988), 53(15), 3450-7

CODEN: JOCEAH; ISSN: 0022-3263

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 109:55060

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB A convergent synthesis of vitamin D3 analogs such as I (active in differentiation of human leukemia HL 60 cells with diminished calcemic activity) was developed, via the common intermediate II.


IT 112924-91-1P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, in synthesis of vitamin D3 analogs)

RN 112924-91-1 CAPLUS

CN 1H-Indene-1-acetaldehyde, 4-[(2Z)-[(3S,5R)-3,5-bis[[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro- $\alpha$ ,7a-dimethyl-, ( $\alpha$ S,1R,3aS,4E,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



OS.CITING REF COUNT: 23 THERE ARE 23 CAPLUS RECORDS THAT CITE THIS RECORD (23 CITINGS)

L10 ANSWER 65 OF 69 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1988:180270 CAPLUS

DOCUMENT NUMBER: 108:180270

ORIGINAL REFERENCE NO.: 108:29437a,29440a

TITLE: Analogs of the hormonal form of vitamin D and their possible use in leukemia

AUTHOR(S): DeLuca, Hector F.; Ostrem, Voula K.

CORPORATE SOURCE: Dep. Biochem., Univ. Wisconsin, Madison, WI, 53706, USA

SOURCE: Progress in Clinical and Biological Research (1988), 259(Nutr., Growth, Cancer), 41-55  
CODEN: PCBRD2; ISSN: 0361-7742

DOCUMENT TYPE: Journal

LANGUAGE: English

AB After a review of the mol. mechanism of action of 1,25-dihydroxyvitamin D<sub>3</sub> (1,25-(OH)<sub>2</sub>D<sub>3</sub>), its possible role in tissues not previously believed to be targets of its action, the presence of 1,25-(OH)<sub>2</sub>D<sub>3</sub> receptors in cancer cell lines, and 1,25-(OH)<sub>2</sub>D<sub>3</sub>-induced differentiation of the stem cells of myeloid cell lines, a large analog study was concluded that suggests that specific analogs of 1,25-(OH)<sub>2</sub>D<sub>3</sub> can be prepared that have markedly enhanced activity in promoting differentiation of HL-60 promyelocytes to benign monocytes. Lengthening the side chain of 1,25-(OH)<sub>2</sub>D<sub>3</sub> increased the activity in HL-60 cells by 1 order of magnitude when the side chain was increased in length by 1 C. At the same time, the biol. activity of these compds. in serum Ca<sup>2+</sup> elevation was either unchanged or diminished. Thus, lengthening the side chain may well provide a preferentially active form of vitamin D on the promyelocytes. Shortening the side chain resulted in a 10-fold loss of activity in HL-60 cells for each C removed. Furthermore, elimination of the 26- and 27-C atoms decreased the biol. activity by 100-fold. If, however, the OH was left off the side chain and small hydrocarbon side chains of Et or Iso-Pr were substituted, very high activity in HL-60 cells was achieved without activity in mobilizing Ca<sup>2+</sup> in vivo. Therefore, these are compds. which illustrate at least in vitro specific activity in HL-60 cells.

IT 111024-92-1

RL: BIOL (Biological study)


(leukemia cell inhibition by, structure in relation to)

RN 111024-92-1 CAPLUS

10/923,271

CN 1H-Indene-1-acetaldehyde, 4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro- $\alpha$ ,7a-dimethyl-, ( $\alpha$ S,1R,3aS,4E,7aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD  
(5 CITINGS)

L10 ANSWER 66 OF 69 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1988:112839 CAPLUS

DOCUMENT NUMBER: 108:112839

ORIGINAL REFERENCE NO.: 108:18504h,18505a

TITLE: Vitamin D analogs for the  
treatment of disorders characterized by abnormal  
proliferation and/or differentiation of cells,  
processes for their preparation, and their  
pharmaceutical formulations

INVENTOR(S): Calverley, Martin John; Binderup, Ernst Torndal

PATENT ASSIGNEE(S): Leo Pharmaceutical Products Ltd., Den.

SOURCE: PCT Int. Appl., 56 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 8700834	A1	19870212	WO 1986-DK81	19860714 <--
W: AU, DK, JP, KR, US				
RW: BE, DE, FR, GB, IT, LU, NL, SE				
AU 8661961	A	19870305	AU 1986-61961	19860714 <--
AU 603340	B2	19901115		
EP 227826	A1	19870708	EP 1986-904788	19860714 <--
EP 227826	B1	19891025		
R: BE, DE, FR, GB, IT, LU, NL, SE				
JP 63500661	T	19880310	JP 1986-504410	19860714 <--
JP 07100685	B	19951101		
CA 1307288	C	19920908	CA 1986-515024	19860730 <--
ES 2000823	A6	19880316	ES 1986-822	19860801 <--

10/923,271

US 4866048	A	19890912	US 1987-34391	19870318 <--
DK 8701429	A	19870320	DK 1987-1429	19870320 <--
DK 166617	B1	19930621		

PRIORITY APPLN. INFO.: GB 1985-19502 A 19850802  
WO 1986-DK81 A 19860714

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 108:112839

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title analogs I [X = H, C1-6 alkyl, halo, OH; Y = H, OH; R1, R2 = C1-6 alkyl (un)substituted by halo or OH; CR1R2 = (un)saturated (un)substituted by C1-6 alkyl, halo, or OH; both R1 and R2  $\neq$  Me when X  $\neq$  C1-6 alkyl; R3 = H, C1-6 alkyl; R4 = R5 = H; R4R5 = bond] are prepared for treating disorders of cell proliferation and/or differentiation (no data). Formylsecopregnatriene derivative II underwent Wittig reaction with (cyclopropylcarbonylmethylene)triphenylphosphorane in Me<sub>2</sub>SO, followed by reduction with NaAlH(OCH<sub>2</sub>CH<sub>2</sub>OMe)<sub>2</sub> in THF, photolytic isomerization in PhMe containing Et<sub>3</sub>N and anthracene, and desilylation with Bu<sub>4</sub>N+F<sup>-</sup>, to give I [X R3 = H, Y = OH, R1R2 = (CH<sub>2</sub>)<sub>2</sub>, R4R5 = trans double bond] (1 of 2 epimers, separated at reduction step).


IT 87407-47-4P 87422-13-7P 112670-80-1P  
112790-51-9P 112828-12-3P 112828-13-4P  
112924-91-1P 112924-92-2P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and reaction of, in synthesis of vitamin D analogs)

RN 87407-47-4 CAPLUS

CN 1H-Indene-1-acetaldehyde, 4-[[[(1R,6S)-6-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1,3,4,5,6,7-hexahydro-2,2-dioxidobenzo[c]thien-1-yl]methylene]octahydro- $\alpha$ ,7a-dimethyl-, ( $\alpha$ S,1R,3aS,4E,7aR)- (CA INDEX NAME)]

Absolute stereochemistry.

Double bond geometry as described by E or Z.



RN 87422-13-7 CAPLUS


CN 1H-Indene-1-acetaldehyde, 4-[[[(1S,6S)-6-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1,3,4,5,6,7-hexahydro-2,2-dioxidobenzo[c]thien-1-yl]methylene]octahydro- $\alpha$ ,7a-dimethyl-,

10/923,271

( $\alpha$ S,1R,3aS,4E,7aR)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as described by E or Z.




RN 112670-80-1 CAPLUS

CN 1H-Indene-1-acetaldehyde, 4-[[[(1S,4S,6R)-4,6-bis[(1,1-dimethylethyl)dimethylsilyl]oxy]-1,3,4,5,6,7-hexahydro-2,2-dioxidobenzo[c]thien-1-yl]methylene]octahydro- $\alpha$ ,7a-dimethyl-, ( $\alpha$ S,1R,3aS,4E,7aR)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 112790-51-9 CAPLUS

CN 1H-Indene-1-acetaldehyde, 4-[[[(1R,4S,6R)-4,6-bis[(1,1-dimethylethyl)dimethylsilyl]oxy]-1,3,4,5,6,7-hexahydro-2,2-dioxidobenzo[c]thien-1-yl]methylene]octahydro- $\alpha$ ,7a-dimethyl-, ( $\alpha$ S,1R,3aS,4E,7aR)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



10/923,271


RN 112828-12-3 CAPLUS  
CN 1H-Indene-1-acetaldehyde, 4-[(2E)-[(5S)-5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro- $\alpha$ ,7a-dimethyl-, ( $\alpha$ S,1R,3aS,4E,7aR)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



RN 112828-13-4 CAPLUS  
CN 1H-Indene-1-acetaldehyde, 4-[(2E)-2-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro- $\alpha$ ,7a-dimethyl-, ( $\alpha$ S,1R,3aS,4E,7aR)- (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 112924-91-1 CAPLUS  
CN 1H-Indene-1-acetaldehyde, 4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro- $\alpha$ ,7a-dimethyl-, ( $\alpha$ S,1R,3aS,4E,7aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.

10/923,271



RN 112924-92-2 CAPLUS  
CN 1H-Indene-1-acetaldehyde, 4-[(2Z)-2-[(5S)-5-[[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro- $\alpha$ ,7 $\alpha$ -dimethyl-, ( $\alpha$ S,1R,3 $\alpha$ S,4E,7 $\alpha$ R)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



OS.CITING REF COUNT: 29 THERE ARE 29 CAPLUS RECORDS THAT CITE THIS RECORD (34 CITINGS)  
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 67 OF 69 CAPLUS COPYRIGHT 2010 ACS on STN  
ACCESSION NUMBER: 1987:591147 CAPLUS  
DOCUMENT NUMBER: 107:191147  
ORIGINAL REFERENCE NO.: 107:30477a,30480a  
TITLE: Induction of monocytic differentiation of HL-60 cells by 1,25-dihydroxyvitamin D analogs  
AUTHOR(S): Ostrem, Voula K.; Lau, Wan Fang; Lee, Seok Ho; Perlman, Kato; Prahl, Jean; Schnoes, Heinrich K.;



CORPORATE SOURCE: DeLuca, Hector F.; Ikekawa, Nobuo  
Dep. Biochem., Univ. Wisconsin, Madison, WI, 53706,  
USA

SOURCE: Journal of Biological Chemistry (1987),  
262(29), 14164-71

CODEN: JBCHA3; ISSN: 0021-9258

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The relative activity of 30 analogs of 1,25-dihydroxyvitamin D3 in inducing development of monocytic markers was assessed in HL-60 cells. The 3 differentiation markers assayed were nonspecific acid esterase activity, nitro blue tetrazolium-reducing activity, and phagocytic capacity. Of the known metabolites of vitamin D, 1,25-dihydroxyvitamin D3 was the most active; 50% of the cells exhibited the mature phenotype following a 4-day treatment with 10<sup>-8</sup>M 1,25-dihydroxyvitamin D3. Removal of either the C-1 or C-25-OH group reduced activity by 2 orders of magnitude, whereas epimerization of the 1 $\alpha$ - to 1 $\beta$ -OH group virtually abolished activity. Elongation of the steroidal side chain of 1,25-dihydroxyvitamin D3 by addition of 1 C atom at C-24 or C-26 improved the potency by an order of magnitude. Truncation of the steroidal side chain led to a 10-fold reduction in activity for each C atom removed. Elimination of the C-26 and C-27 Me groups reduced activity 100-fold. Analogs with short aliphatic side chains as 1 $\alpha$ -hydroxyhomo- and bishomopregnacholecalciferol had surprisingly high activity, being only 20-fold less potent than the natural hormone. The activity of most analogs in the HL-60 system paralleled their known relative affinities for the well-characterized 1,25-dihydroxyvitamin D3 receptor in chick intestine, thus providing further evidence that this function of 1,25-dihydroxyvitamin D3 is receptor mediated.

IT 111024-92-1

RL: BIOL (Biological study)


(monocytic differentiation induction by, structure in relation to)

RN 111024-92-1 CAPLUS

CN 1H-Indene-1-acetaldehyde, 4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro- $\alpha$ ,7a-dimethyl-, ( $\alpha$ S,1R,3aS,4E,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



OS.CITING REF COUNT: 33 THERE ARE 33 CAPLUS RECORDS THAT CITE THIS  
RECORD (33 CITINGS)

L10 ANSWER 68 OF 69 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1983:595277 CAPLUS  
 DOCUMENT NUMBER: 99:195277  
 ORIGINAL REFERENCE NO.: 99:30071a,30074a  
 TITLE: 1-Hydroxylated vitamin D compounds  
 INVENTOR(S): Hesse, Robert Henry  
 PATENT ASSIGNEE(S): Research Institute for Medicine and Chemistry, Inc.,  
 USA  
 SOURCE: Eur. Pat. Appl., 35 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 78705	A1	19830511	EP 1982-305822	19821102 <--
EP 78705	B1	19880427		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
GB 2108506	A	19830518	GB 1982-31300	19821102 <--
GB 2108506	B	19850807		
JP 58126862	A	19830728	JP 1982-191956	19821102 <--
JP 03053299	B	19910814		
ZA 8208012	A	19830928	ZA 1982-8012	19821102 <--
IL 67152	A	19860731	IL 1982-67152	19821102 <--
CA 1221707	A1	19870512	CA 1982-414662	19821102 <--
AT 33828	T	19880515	AT 1982-305822	19821102 <--
US 4554105	A	19851119	US 1984-648309	19840907 <--
US 4772433	A	19880920	US 1986-827553	19860210 <--
PRIORITY APPLN. INFO.:			GB 1981-33019	A 19811102
			GB 1981-33021	A 19811102
			GB 1981-33018	A 19811102
			EP 1982-305822	A 19821102
			US 1982-438603	A1 19821102
			US 1982-438604	A1 19821102
			US 1984-568620	A1 19840106
			US 1984-568891	A1 19840106
			US 1984-650891	A1 19840917

OTHER SOURCE(S): MARPAT 99:195277

AB Antirachitic (no data) 1-hydroxy vitamin D compds.  
 were prepared by Se+4 allylic hydroxylation of C-1 unsubstituted 5,6-trans-  
 vitamin D compds. in the presence of selenous acid at pH  
 3-9 and in the presence of a co-oxidant capable of oxidation of Se+2 compds.  
 to Se+4 compds. Thus, treating trans-vitamin D3 tert-butyldimethylsilyl  
 ether with N-methylmorpholine oxide hydrate in CH<sub>2</sub>Cl<sub>2</sub> and then with SeO<sub>2</sub>  
 in MeOH gave 52% 1 $\alpha$ -hydroxy-3-(tert-butyldimethylsiloxy)-trans-  
 vitamin D<sub>3</sub>. Photochem. isomerization of the latter and then desilylation  
 by Bu<sub>4</sub>N+F<sup>-</sup> gave 1 $\alpha$ -hydroxy-cis-vitamin D<sub>3</sub>.

IT 87680-62-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation and reduction of)

RN 87680-62-4 CAPLUS

CN 1H-Indene-1-acetaldehyde, 4-[[1,3,4,5,6,7-hexahydro-2,2-dioxido-6-

10/923,271

[(triethylsilyl)oxy]benzo[c]thien-1-yl]methylene]octahydro- $\alpha$ ,7a-dimethyl- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD  
(1 CITINGS)

L10 ANSWER 69 OF 69 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1983:576164 CAPLUS

DOCUMENT NUMBER: 99:176164

ORIGINAL REFERENCE NO.: 99:27049a,27052a

TITLE: Intermediates in the synthesis of vitamin  
D derivatives

INVENTOR(S): Hesse, Robert Henry

PATENT ASSIGNEE(S): Research Institute for Medicine and Chemistry, Inc.,  
USA

SOURCE: Eur. Pat. Appl., 75 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 78704	A1	19830511	EP 1982-305821	19821102 <--
EP 78704	B1	19870429		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
JP 58126861	A	19830728	JP 1982-191955	19821102 <--
JP 02024268	B	19900529		
GB 2114570	A	19830824	GB 1982-31299	19821102 <--
GB 2114570	B	19850807		
ZA 8208012	A	19830928	ZA 1982-8012	19821102 <--
ZA 8208011	A	19840125	ZA 1982-8011	19821102 <--
CA 1204752	A1	19860520	CA 1982-414661	19821102 <--
IL 67153	A	19861231	IL 1982-67153	19821102 <--
AT 26838	T	19870515	AT 1982-305821	19821102 <--
US 4554105	A	19851119	US 1984-648309	19840907 <--
US 4772433	A	19880920	US 1986-827553	19860210 <--
JP 02000163	A	19900105	JP 1989-109265	19890501 <--

10/923,271

JP 05067627  
PRIORITY APPLN. INFO.:

B 19930927

GB 1981-33018	A 19811102
GB 1981-33019	A 19811102
GB 1981-33021	A 19811102
EP 1982-305821	A 19821102
US 1982-438603	A1 19821102
US 1982-438604	A1 19821102
US 1984-568620	A1 19840106
US 1984-568891	A1 19840106
US 1984-650891	A1 19840917

OTHER SOURCE(S): MARPAT 99:176164  
GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Secosteroid cycloadducts I [R = H, protecting group; X = dienophile moiety; R1 = halo, hydrocarbylsulfonyloxy, X1R4 (X1 = O, S, SO, NR5, CR5R6; R4, R5, R6 = H, alkyl); R2 = H; R1R2 = O, alkylidene; R3 = H, protected HO] were prepared from ergosterol as intermediates in the synthesis of vitamin D analogs. Thus, cyclization of ergosterol acetate and phthalazine-1,4-dione gave adduct II, which underwent successive ozonolysis, reduction, and tosylation to give tosylate III. Substitution reaction of III with HSCH2CMe2OH followed by removal of the phthalazine blocking group by hydrazinolysis and treatment with dianisyltellurium oxide-K2CO3 gave thiacholestatriene IV.


IT 87417-05-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reduction and Wittig reactions of)

RN 87417-05-8 CAPLUS


CN 1H-Indene-1-acetaldehyde, 4-[[3-(acetyloxy)-1,2,3,4,5,7,12,14-octahydro-7,12-dioxophthalazino[2,3-b]phthalazin-5-yl]methylene]octahydro- $\alpha$ ,7 $\alpha$ -dimethyl-, [1R-[1 $\alpha$ (S\*),3 $\alpha$  $\beta$ ,4E(3S\*,5R\*),7 $\alpha$ ]]- (9CI) (CA INDEX NAME)




10/923,271

IT 87407-47-4P 87407-48-5P 87417-06-9P  
87422-13-7P 87422-14-8P 87436-42-8P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation and reduction of)  
RN 87407-47-4 CAPLUS  
CN 1H-Indene-1-acetaldehyde, 4-[[[(1R,6S)-6-[[[(1,1-  
dimethylethyl)dimethylsilyl]oxy]-1,3,4,5,6,7-hexahydro-2,2-  
dioxidobenzo[c]thien-1-yl]methylene]octahydro- $\alpha$ ,7a-dimethyl-,  
( $\alpha$ S,1R,3aS,4E,7aR)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as described by E or Z.




RN 87407-48-5 CAPLUS  
CN 1H-Indene-1-acetaldehyde, 4-[[[1,3,4,5,6,7-hexahydro-2,2-dioxido-6-  
[(triethylsilyl)oxy]benzo[c]thien-1-yl]methylene]octahydro- $\alpha$ ,7a-  
dimethyl-, [1R-[1 $\alpha$ (S\*),3a $\beta$ ,4E(1R\*,6S\*),7a $\alpha$ ]]- (9CI) (CA  
INDEX NAME)



RN 87417-06-9 CAPLUS  
CN 1H-Indene-1-acetaldehyde, octahydro- $\alpha$ ,7a-dimethyl-4-  
[[[1,2,3,4,5,7,12,14-octahydro-7,12-dioxo-3-[(tetrahydro-2H-pyran-2-  
yl)oxy]phthalazino[2,3-b]phthalazin-5-yl]methylene]-,  
[1R-[1 $\alpha$ (S\*),3a $\beta$ ,4E(3S\*,5R\*),7a $\alpha$ ]]- (9CI) (CA INDEX NAME)

10/923,271




RN 87422-13-7 CAPLUS

CN 1H-Indene-1-acetaldehyde, 4-[[[(1S,6S)-6-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1,3,4,5,6,7-hexahydro-2,2-dioxidobenzo[c]thien-1-yl]methylene]octahydro- $\alpha$ ,7a-dimethyl-, ( $\alpha$ S,1R,3aS,4E,7aR)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as described by E or Z.




RN 87422-14-8 CAPLUS

CN 1H-Indene-1-acetaldehyde, 4-[[[1,3,4,5,6,7-hexahydro-2,2-dioxido-6-[(triethylsilyl)oxy]benzo[c]thien-1-yl]methylene]octahydro- $\alpha$ ,7a-dimethyl-, [1R-[1 $\alpha$ (S\*),3 $\alpha$  $\beta$ ,4E(1S\*,6S\*),7 $\alpha\alpha$ ]]- (9CI) (CA INDEX NAME)

10/923,271




RN 87436-42-8 CAPLUS  
 CN 1H-Indene-1-acetaldehyde, 4-[[3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1,2,3,4,5,7,12,14-octahydro-7,12-dioxophthalazino[2,3-b]phthalazin-5-yl]methylene]octahydro- $\alpha$ ,7a-dimethyl-, [1R-[1 $\alpha$ (S\*), 3a $\beta$ , 4E(3S\*, 5R\*), 7a $\alpha$ ]]- (9CI) (CA INDEX NAME)




IT 87416-99-7P 87417-07-0P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 87416-99-7 CAPLUS  
 CN 1H-Indene-1-acetaldehyde, octahydro- $\alpha$ ,7a-dimethyl-4-[(2,3,5,6,7,8,9,10-octahydro-7-hydroxy-1,3-dioxo-2-phenyl-1H-[1,2,4]triazolo[1,2-b]phthalazin-5-yl)methylene]-, [1R-[1 $\alpha$ (S\*), 3a $\beta$ , 4E(5R\*, 7S\*), 7a $\alpha$ ]]- (9CI) (CA INDEX NAME)

10/923,271



RN 87417-07-0 CAPLUS

CN 1H-Indene-1-acetaldehyde, octahydro- $\alpha$ ,7a-dimethyl-4-  
[[1,2,3,4,5,7,12,14-octahydro-3-[(2-methoxyethoxy)methoxy]-7,12-  
dioxophthalazino[2,3-b]phthalazin-5-yl]methylene]-,  
[1R-[1 $\alpha$ (S\*),3 $\alpha\beta$ ,4E(3S\*,5R\*),7 $\alpha\alpha$ ]]- (9CI) (CA INDEX NAME)



OS.CITING REF COUNT: 18 THERE ARE 18 CAPLUS RECORDS THAT CITE THIS  
RECORD (19 CITINGS)